Thomas Kipps, MD, PhD
The CLL Research Consortium (CRC) is a multi-institutional program project, funded, in part, by the National Institute of Health. The consortium has brought together institutions that, under normal circumstances, would not engage one another as they currently can under the auspices of CRC. The Consortium includes the following clinical sites: Moores UCSD Cancer Center, M.D. Anderson Cancer Center, Ohio State University Cancer Center, North Shore-Long Island Jewish Medical System, Dana-Farber Cancer Institute, Mayo Clinic, and several sites that perform laboratory work alone, including The Burnham Institute and Barts and the London Cancer Center. These institutions see a diverse patient population and all possess high quality basic science laboratories. Bringing these sites together in the context of the CRC has resulted in a program that is much more than the sum of its parts.
Currently there are seven clinical sites in the CRC. These institutions see a diverse patient population and all possess high quality basic science laboratories.
The CRC is developing new and innovative curative strategies for CLL.
Answers to the questions, what is Chronic Lymphocytic Leukemia (CLL) & what causes CLL? A glossary of terms and the latest publications & articles.